Press release
Global Non-Alcoholic Steatohepatitis (NASH) Market Outlook 2025-2034: Trends, Innovations, And Future Outlook
Non-Alcoholic Steatohepatitis (NASH)
What Is the Expected Non-Alcoholic Steatohepatitis (NASH) Market Size During the Forecast Period?
In recent times, the market size for non-alcoholic steatohepatitis (NASH) has seen a considerable surge. It is projected to swell from $4.5 billion in 2024 up to $6.13 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 36.1%. This noticeable advancement during the historical period is majorly due to factors such as an increase in NASH cases, the growing obesity crisis, heightened awareness and diagnosis rates, lifestyle modifications, changes in eating habits, and the evolution of healthcare infrastructure.
In the upcoming years, the market size for non-alcoholic steatohepatitis (NASH) is predicted to experience remarkable growth, expanding to $19.07 billion by 2029 with a compound annual growth rate (CAGR) of 32.8%. This growth trajectory during the forecast period can be credited to the progress in NASH drug development, the escalation in NASH screening initiatives, increased healthcare spending, collective research contributions, and governmental backing and regulations. The forecast period will also see major trends like the emphasis on lifestyle interventions and patient education, enhanced collaborative efforts in clinical research, regulatory progress and pathway designations, along with the incorporation of artificial intelligence in disease diagnosis and monitoring.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8805
What Are the High-Growth Segments in the Non-Alcoholic Steatohepatitis (NASH) Market?
The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented -
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp
What Key Drivers Are Expected to Influence Future Non-Alcoholic Steatohepatitis (NASH) Market Growth?
The escalating incidences of obesity are propelling the need for non-alcoholic steatohepatitis (NASH) market growth. Obesity, defined as an undue or extreme accumulation of fat that threatens health status, as well as body weight exceeding the normal range for a certain height, is increasingly prevalent. As non-alcoholic fatty liver disease gains prominence owing to the progressive obesity crisis, NASH has the potential to become the most common cause of intense liver disease in the approaching years, hence, fueling the demand for NASH therapies and related medications. As an example, the World Health Organization (WHO), a UK-based global public health agency, reported in March 2024 that in 2022, around 2.5 billion adults aged 18 and above were considered overweight, of whom 890 million were suffering from obesity. Consequently, the augmenting instances of obesity will stimulate the expansion of the non-alcoholic steatohepatitis (NASH) market.
Which Companies Hold the Largest Share Across Different Non-Alcoholic Steatohepatitis (NASH) Market Segments?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
What Are the Latest Developing Trends in the Non-Alcoholic Steatohepatitis (NASH) Market?
Key players in the non-alcoholic steatohepatitis (NASH) market are focusing on the development of thyroid hormone receptor-beta (THR-beta) agonists. These compounds have the potential to boost liver metabolism, limit the buildup of liver fat, and enhance liver function. THR-beta agonists are unique in their ability to selectively activate the thyroid hormone receptor-beta subtype, which plays a critical role in the control of metabolism, growth, and maturation. For example, in March 2024, Rezdiffra (resmetirom), a THR-beta agonist, received approval from the US-based Food and Drug Administration as the first therapy for adults suffering from noncirrhotic NASH ranging from moderate to severe liver fibrosis. Rezdiffra's ability to selectively stimulate the THR-beta receptor aids in lipid metabolism management, leading to a decrease in intrahepatic triglycerides and overall liver fat accumulation.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report
What Are the Emerging Geographies for The Non-Alcoholic Steatohepatitis (NASH) Market Growth?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Non-Alcoholic Steatohepatitis (NASH) Market?
2. What is the CAGR expected in the Non-Alcoholic Steatohepatitis (NASH) Market?
3. What Are the Key Innovations Transforming the Non-Alcoholic Steatohepatitis (NASH) Industry?
4. Which Region Is Leading the Non-Alcoholic Steatohepatitis (NASH) Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Non-Alcoholic Steatohepatitis (NASH) Market Outlook 2025-2034: Trends, Innovations, And Future Outlook here
News-ID: 4014503 • Views: …
More Releases from The Business Research Company
Seed Treatment Fungicides Market to Grow at 9.3% CAGR, Reaching $3.15 Billion by …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Seed Treatment Fungicides Market Outlook: How is the Market Expected to Grow by 2025?
Over the past few years, the market for seed treatment fungicides has seen robust growth. Its market value is projected to rise from $2.07 billion in 2024 to $2.21 billion in 2025, signifying a compound annual…
Rheology Modifiers Market Growth to be Driven by Emerging Trends | $10.92 Billio …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Rheology Modifiers Industry?
There has been a consistent expansion in the size of the rheology modifiers market in the past few years. The market, which was worth $8.59 billion in 2024, is projected to increase to $8.89 billion in 2025, demonstrating a compound…
Polyurethane Foam Market to Record 8.4% CAGR Growth Through 2029 | Global Analys …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Polyurethane Foam Market Outlook: How is the Market Expected to Grow by 2025?
In recent years, the size of the polyurethane foam market has experienced substantial growth. It is projected to increase from a value of $54.27 billion in 2024 to $57.26 billion in 2025, indicating a compound annual growth…
Pharmaceutical Intermediates Market Size to Reach $46.04 Billion by 2029 | Growt …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What is the Projected Market Size of the Pharmaceutical Intermediates Industry?
There has been consistent growth in the market size of pharmaceutical intermediates over the past few years. The market is predicted to increase from a value of $33.37 billion in 2024, up to $34.95 billion in 2025, with a compound…
More Releases for NASH
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
